The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
N Papadopoulos, KW Kinzler, B Vogelstein - Nature biotechnology, 2006 - nature.com
Among all the known differences between cancer and normal cells, it is only the genetic
differences that unequivocally distinguish the former from the latter. It is therefore not …
differences that unequivocally distinguish the former from the latter. It is therefore not …
Imatinib and beyond—exploring the full potential of targeted therapy for CML
A Quintas-Cardama, H Kantarjian… - Nature reviews Clinical …, 2009 - nature.com
A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will
require alternative therapy at some point owing to safety reasons or lack of efficacy …
require alternative therapy at some point owing to safety reasons or lack of efficacy …
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early …
A Quintás-Cardama, H Kantarjian… - Blood, The Journal …, 2009 - ashpublications.org
Patients not in complete cytogenetic response (CCyR) continuously face the competing
possibilities of eventually achieving a cytogenetic response versus progressing. We …
possibilities of eventually achieving a cytogenetic response versus progressing. We …
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
F Efficace, M Baccarani, M Breccia, F Cottone… - Leukemia, 2013 - nature.com
Health-related quality of life (HRQOL) is an important goal of therapy for chronic myeloid
leukemia (CML) patients treated with current molecular-targeted therapies. The main …
leukemia (CML) patients treated with current molecular-targeted therapies. The main …
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri… - Blood, The Journal …, 2011 - ashpublications.org
The median age of chronic myeloid leukemia (CML) patients is∼ 60 years, and age is still
considered an important prognostic factor, included in Sokal and EURO risk scores …
considered an important prognostic factor, included in Sokal and EURO risk scores …
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML …
F Castagnetti, F Palandri, M Amabile… - Blood, The Journal …, 2009 - ashpublications.org
Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML):
the standard dose for chronic-phase (CP) CML is 400 mg daily. Response rates are different …
the standard dose for chronic-phase (CP) CML is 400 mg daily. Response rates are different …
[HTML][HTML] Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
G Rosti, I Iacobucci, S Bassi, F Castagnetti… - …, 2007 - haematologica.org
To assess the effect of age on response and compliance to treatment in patients with chronic
myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA …
myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA …
Response-related predictors of survival in CML
B Hanfstein, MC Müller, A Hochhaus - Annals of hematology, 2015 - Springer
The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid
leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be …
leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be …
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA …
F Palandri, I Iacobucci, G Martinelli… - Journal of clinical …, 2008 - ascopubs.org
Purpose Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-
positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated …
positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated …
Different kinetic patterns of BCR‐ABL transcript levels in imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response
YZ Qin, YR Liu, HH Zhu, JL Li, GR Ruan… - International Journal …, 2008 - Wiley Online Library
Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …